Durvalumab and olaparib with chemotherapy improve progression-free survival in first-line metastatic endometrial cancer: a new promising combination strategy?

Gynecol Pelvic Med · 2025 · PMC13215032 · PMID 42211915

Europe PMC DOI

hedged sentence

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

showed a trendP=0.12not close (p > 0.1)

Interim OS data showed a trend towards benefit for both combination arms compared to CP alone (P=0.12 with CP + durvalumab versus CP; HR, 0.77; P=0.003 with CP + durvalumab + olaparib vs.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.